drugset / Trial / NCT05900895
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
NaSequentialOpen-labelTreatment
Summary
Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
Timeline
- Start
- 2024-07-15
- Primary completion
- 2027-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Estradiol | Other / unclassified | — | Oral |
| Subject | Olaparib | Small molecule | — | — |